For Alberta and Green Shield Canada, savings are beginning to add up from switching initiatives for multiple reference biologics.
Recognizing the swift upward march of biologics prices and the savings potential of biosimilars, which are cheaper versions of original brand biologics, various entities in Canada have imposed switching policies to get patients off costly reference drugs. They have been successful thus far, officials reported at the recent Festival of Biologics USA.
In December 2019, the Canadian province of Alberta initiated mandatory biosimilar switching for patients enrolled in government drug plans for individuals without private coverage, seniors, and low-income groups.
Chad Mitchell, assistant deputy minister for Alberta Health, said biologics account for 72% of total drug spending in the province and that the cost of these agents has been going up 14% yearly. Just 4 originator drugs have accounted for as much as 75% of the biologics spend: Remicade (infliximab), Humira (adalimumab), Enbrel (etanercept), and Stelara (ustekinumab).
The COVID-19 pandemic has forced the government to stretch out the switching transition, but Alberta anticipates $30 million in savings from biosimilars annually. Under the switching program, coverage is initiated on biosimilars once they become available, and access to biologics is tiered so that patients must try cost-effective therapies first, including biosimilars.
In Alberta, patients were switched from infliximab, etanercept, pegfilgrastim, and filgrastim originator biologics. They were also switched from insulin glargine and glatiramer originators, although in the United States there are no official biosimilars for these products yet.
Alberta ran into some problems. For example, some pharmacies began stocking only preferred biosimilars, which meant that patients and their providers could not choose. Alberta has attempted to remedy this problem.
The government has succeeded in switching over 60% of patients from reference infliximab to biosimilar infliximab, but there has been opposition. In addition, more than 15% of patients moved to a different biologic and roughly 15% dropped or terminated their government coverage, Mitchell said. The government is attempting to find out the reasons for these coverage departure and treatment changes.
For the originator insulin glargine product Lantus, more than 40% of patients moved to a different biologic after switching was initiated, and 15% of beneficiaries dropped or terminated their coverage. Mitchel said 10% to 20% of beneficiaries in other biosimilar categories terminated coverage. More investigation is needed to understand the significance of these trends, he said.
Green Shield Canada
On the payer side, Green Shield Canada (GSC) reported success with biosimilar switching initiatives for patients with rheumatic conditions. Nedzad Pojskic, PhD, MSc, vice president of Pharmacy Benefits Management for GSC, said the key to success was ensuring that patients and providers had an incentive to use the lower-cost biosimilar. Simply having biosimilars on formulary is not enough, he said. It’s important to make sure biosimilars have preferred status.
Pojskic said 55% of patients in the GSC program have transitioned to a biosimilar and $8500 of savings has been generated per member annually. GSC announced in February 2018 that it would initiate a pilot program preferentially listing biosimilars on formulary for treatment-naïve patients.
For more about Pojskic’s presentation, click here.
The Supreme Court seems likely to reject a challenge to the abortion pill mifepristone; the FDA is inspecting far fewer pharmaceutical companies conducting clinical research; AstraZeneca has sued to block an Arkansas law that it said would unlawfully expand the 340B program to include for profit-pharmacy chains.
Read More
Exploring Medicare Advantage Prior Authorization Variations
March 26th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the March 2024 issue of The American Journal of Managed Care® about their findings on variations in prior authorization use across Medicare Advantage plans.
Listen
Mirvetuximab Soravtansine-gynx Granted Full FDA Approval for FRα+ Platinum-Resistant Ovarian Cancer
March 22nd 2024Mirvetuximab soravtansine-gynx (Elahere) received full FDA approval for the treatment of folate receptor alpha–positive (FRα+), platinum-resistant ovarian cancer (PROC) based on findings from the confirmatory phase 3 MIRASOL trial.
Read More
Navigating Health Literacy, Social Determinants, and Discrimination in National Health Plans
February 13th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the February 2024 issue of The American Journal of Managed Care® about their findings on how health plans can screen for health literacy, social determinants of health, and perceived health care discrimination.
Listen
The White House has called out the Republican Study Committee’s budget proposal for backing legislation that would put restrictions on abortion access; nearly 108,000 Americans died of drug overdoses in 2022; surgeons in Boston have transplanted a kidney from a genetically engineered pig into an ailing 62-year-old man.
Read More
A global AIDS program that was in limbo for months got temporary relief after congressional negotiators agreed to a 1-year renewal in the next government funding package; the outcome of the November presidential election could determine the state of fetal tissue research in the US; federal officials and industry executives failed to make improvements that stop hacking attacks.
Read More